FC131 TFA

CAS No. ——

FC131 TFA( —— )

Catalog No. M22521 CAS No. ——

FC131 TFA is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 828 In Stock
10MG 1382 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FC131 TFA
  • Note
    Research use only, not for human use.
  • Brief Description
    FC131 TFA is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.
  • Description
    FC131 TFA is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR4|HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    843.85
  • Molecular Formula
    C38H48F3N11O8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (296.26 mM; Need ultrasonic)
  • SMILES
    FC(F)(F)C(=O)O.N=C(N)NCCC[C@@H]4NC(=O)[C@@H](NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](Cc2cc3ccccc3cc2)NC4=O)CCCNC(=N)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Tamamura H, et al. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem. 2005 Jan 27;48(2):380-91.
molnova catalog
related products
  • CXCL-CXCR1/2-IN-1

    CXCL-CXCR1/2-IN-1 is an orally active and potent inhibitor of the ELR+CXCL-CXCR1/2 pathway with anticancer and anti-angiogenic activity and can be used to study cardiovascular disease and cancer.

  • AZD8797

    AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2.

  • NUCC-390

    NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100.